15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Vaxcyte Inc, 2 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $38.00 to $116.00 (about 3.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $81.00 sits 48% above the current $54.58. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-2.16 next quarter toward $-7.42 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy267%
Hold133%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Vaxcyte Inc.
As of Jul, 2 of 3 firms rate PCVX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PCVX EPS & revenue forecast
EPS · NEXT QUARTER
$-2.16
Range $-2.66 – $-1.68 · 7 analysts · +39% YoY
Next period, 7 analysts expect Vaxcyte Inc to earn $-2.16 a share (range $-2.66 – $-1.68), versus $-1.56 a year earlier. Full-year consensus is $-8.48, growing to $-7.42 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $87.1M next year.
Top analysts covering Vaxcyte Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PCVX.
#1
Jason Gerberry
B of A Securities · Rank #136
Buy
No targeton PCVX
Overall win rate
46%
+ Follow
#2
Louise Chen
Cantor Fitzgerald · Rank #156
Buy
No targeton PCVX
Overall win rate
43%
+ Follow
#3
Joseph Stringer
Needham · Rank #168
Buy
$110.00+101.5% to target
Overall win rate
36%
+ Follow
#4
Thomas Shrader
BTIG
Buy
$89.00+63.1% to target
Coverage
—
+ Follow
#5
AH
Asad Haider
Goldman Sachs
Hold
$67.00+22.8% to target
Coverage
—
+ Follow
PCVX stock forecast FAQ
What is PCVX's average 12-month price target?+
The 3 analysts with a live target average $81.00 for Vaxcyte Inc over the next 12 months, ranging from a $116.00 high to a $38.00 low.
Is PCVX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 2 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PCVX?+
The Street-high target is $116.00 (Guggenheim), and the Street-low is $38.00 (Goldman Sachs). The average of all 3 active targets is $81.00.
How many Wall Street analysts cover PCVX?+
3 analysts have an active rating on Vaxcyte Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering PCVX?+
Among analysts who currently cover PCVX, Jason Gerberry of B of A Securities has the strongest overall Quantellect track record (Rank #136). Their current call is Buy.
What is Vaxcyte Inc's projected EPS for next quarter?+
The consensus estimate is $-2.16 per share (range $-2.66 – $-1.68) across 7 analysts. Full-year EPS is projected at $-8.48, rising to $-7.42 the following year.
How much revenue is Vaxcyte Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $87.1M next year.
Have analysts been upgrading or downgrading PCVX lately?+
As of Jul, 2 of 3 firms rate PCVX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PCVX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
